Your money can buy more shares of these promising companies thanks to an affordable stock price.
News & Analysis: Codexis
The enzyme engineering platform has $93 million in cash and no shortage of growth opportunities. Can it execute?
CDXS earnings call for the period ending June 30, 2019.
These low-priced shares should be on your radar.
The biotech expects double-digit revenue growth in 2019, but shares have fallen 21% since the end of March.
The small-cap biotech now has three of the top 10 pharmaceutical companies using its protein engineering platform technology.
CDXS earnings call for the period ending March 31, 2019.
Offset the rising cost of education with these three companies.
Investors with a long-term mind-set can look to these three stocks to inject growth into their portfolio.
These two companies saw their shares double in 2018. They're still buys for long-term investors.